HOME >> MEDICINE >> NEWS
Twice daily imatinib could improve outcome for people with specific form of gastro-intestinal cancer

This release is also available in German.

Results of a randomised trial in this week's issue of THE LANCET suggest that a single daily 400 mg dose of imatinib--known to be a first-choice treatment for gastro-intestinal stromal tumours (GIST)--is sufficient to induce a therapeutic response; a doubling of a daily dose can slightly improve progression-free survival for patients.

Imatinib is approved worldwide for use in GIST, tumours which do not respond to conventional chemotherapy, which have a prevalence of around 20 per 100,000 population. Jaap Verweij (Erasmus University Medical Center, Netherlands) and colleagues from the European Organisation for Research and Treatment of Cancer (EORTC), the Italian Sarcoma Group (IRG), and the australasian Gastrointestinal Trials Group (AGITG) studied 946 patients with metastatic GIST who were randomly allocated either imatinib 400 mg once or twice a day.

50% of patients receiving two doses of imatinib a day, compared with 56% of patients given a single dose, were alive and free of disease progression at around 2 years follow-up. There was no difference in the proportion of patients (99%) who reported treatment side-effects; the optimum time for therapeutic effect after the start of treatment did not differ between the two groups (around 4 months).

Dr Verweij comments: "If the aim of treatment is response induction, a daily dose of 400 mg given for 46 months seems to be sufficient. However, in patients with widespread metastatic disease, the prolonged progression-free survival achieved with 400 mg twice daily might lead one to favour this regimen. Whether a similar outcome could be achieved with fewer side-effects by making use of the reduction in drug clearance over time--eg, with a starting dose of 400 mg daily followed by stepwise dose escalation to 400 mg twice a day--is still a matter for further clini
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
1-212-633-3810
Lancet
23-Sep-2004


Page: 1 2

Related medicine news :

1. Study: Among Heart Failure Patients, Women Survive Twice As Long As Men
2. Bullying among sixth graders a daily occurrence, UCLA study finds
3. Current daily smoking may be associated with increased risk for suicidal thoughts and attempts
4. African children with HIV would benefit from daily doses of cheap antibiotic
5. Weekend use matches daily drops for lazy eye
6. New ways identified to treat lazy eye in children: Beyond eye patches and daily drops
7. Weekly cycles of once-daily anti-HIV drugs could reduce cost of HIV treatment
8. Study finds once-daily Valcyte prevents serious viral infection after kidney transplant
9. Max daily OTC dose of acetaminophen shows efficacy comparable to Rx doses of naproxen for OA pain
10. New study finds even a small amount of psoriasis can negatively impact daily life
11. OHSU study shows four daily servings of fruits & vegetables reduce breast cancer risk by half

Post Your Comments:
(Date:8/20/2014)... 20, 2014 BCC Research ( ... PHOTONIC SENSORS AND DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS ... is expected to grow to $15.2 billion by ... (CAGR) of 15.9%. Increasing industrialization is driving ... a rapidly expanding range of industrial applications such ...
(Date:8/20/2014)... A Missouri federal judge has remanded a lawsuit filed ... GranuFlo and NaturaLyte to the City of St. Louis Circuit ... The judge rejected an assertion by the defendants that the ... et al. v. Fresenius Medical Care North America Inc., et ... the manufacturer of the dialysis products GranuFlo and NaturaLyte. In ...
(Date:8/20/2014)... (HealthDay News) -- Leaving the car at home and getting ... for your health, a new study indicates. Researchers looked ... that 76 percent of men and 72 percent of women ... of women used public transit, and 14 percent of men ... who drove to work weighed more and had higher levels ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... leading nonprofit authority on the use of health ... announced the full agenda for its annual fall ... IT Efficiency. WEDI-Con 2014 will take place at ... 20-23, 2014, attracting a diverse cross-section of payers, ...
(Date:8/20/2014)... Parents and kids across the nation are ... means buying textbooks and arranging after school care, there ... part of the annual re-commitment to your child’s education; ... Association, 27% of students say they experience "extreme stress" ... are stressed by school pressures. The study, Stress in ...
Breaking Medicine News(10 mins):Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:Want to Stay Slim? Leave the Car at Home 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 2Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 3
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim today ... (FDA) accepted for review the New Drug Application ... and olodaterol delivered via the Respimat ® ... maintenance treatment of airflow obstruction in patients with ... and/or emphysema. Tiotropium + olodaterol FDC will not ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
Breaking Medicine Technology:Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2
Cached News: